Clinical trials
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric cancer or gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 1,155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06361316Recruiting
Liposomal irinotecan with chemo after pancreatic cancer surgery
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT06383767RecruitingPhase 3
A study of ESG401 for advanced HR+/HER2- breast cancer
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06463028RecruitingPhase 2
Targeted pills plus chemo for advanced endometrial cancer
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
La Jolla, CaliforniaAges 18 years+ - NCT06478108RecruitingPhase 2/Phase 3
Software-guided multi-immunotherapy for solid tumors
This trial tests a new software-guided approach to deliver multiple immunotherapy drugs directly into the liver for people with solid tumors. It aims to see if this method can shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT06483347RecruitingPhase 2
Immunotherapy combo for inoperable lung cancer
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT05441163Recruiting
Nutrition and exercise program for frail advanced digestive cancer patients
This study tests whether a personalized plan for food (nutrition) and safe, adapted exercise can improve care in frail people with advanced digestive cancers. You may be more likely to feel stronger and better supported during first-line cancer treatment.
Tours, Institut CurieAges 18 years+ - NCT06519292Recruiting
Heart side effects from immunotherapy in cancer patients
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
Amsterdam, North HollandAges 50 years+ - NCT06529718RecruitingPhase 2
Ivonescimab vs FOLFOX for advanced bile duct cancer
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
AmiensAges 18 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Birmingham, AlabamaAges 18 years+ - NCT06613438Recruiting
New wearable device for GERD symptoms
This study tests a new wearable device (eGERD) that aims to reduce symptoms of GERD (heartburn and regurgitation). The trial will check if the device is safe and works well without needing medication.
Chicago, IllinoisAges 22–75 - NCT06705686RecruitingPhase 1
New drug for advanced prostate cancer
This trial tests an experimental drug called (R)-9b for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can help control the cancer.
Madison, WisconsinAges 18 years+ - NCT06706752Recruiting
Shengbai oral formula for chemotherapy side effects
This study tests if a Chinese herbal formula called Shengbai can safely reduce side effects from chemotherapy. It might help you feel better during cancer treatment.
Oakland, CaliforniaAges 18–80 - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06732323RecruitingPhase 3
Study of ESG401 for triple-negative breast cancer that has spread
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
BeijingAges 18 years+ - NCT06736717RecruitingPhase 1/Phase 2
Testing onvansertib plus chemo for first-line advanced pancreatic cancer
This trial tests a new drug called onvansertib combined with standard chemotherapy (NALIRIFOX) as the first treatment for advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to see if adding onvansertib helps shrink tumors or slow the cancer better than chemo alone.
Kansas City, KansasAges 18 years+ - NCT06761651RecruitingPhase 1
TAVO412 for advanced solid tumors with EGFR, MET, or VEGF changes
This trial tests a new drug, TAVO412, for people with advanced solid tumors that have not responded to other treatments. It focuses on cancers with specific markers (EGFR, MET, or VEGF) and aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06778382RecruitingPhase 2
Delaying treatment after destroying lung spots from colorectal cancer
This trial tests if it's safe to wait before starting full-body therapy after treating a small number of lung tumors (5 or fewer) in people whose colorectal cancer had been gone for at least 6 months. You would first get local treatments like surgery or radiation to destroy the lung spots, then delay additional cancer drugs to see how you do.
Jinan, ShandongAges 18–75 - NCT06787911RecruitingPhase 2
Donafenib and immunotherapy before surgery for advanced thyroid cancer
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
ShanghaiAges 18–80 - NCT06834672RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This trial tests a new drug called IBI354 against standard chemotherapy for people with ovarian, primary peritoneal, or fallopian tube cancer that stopped responding to platinum-based treatments. It aims to see if the new drug works better and has fewer side effects.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06836869Recruiting
Modified surgery for early cervical cancer
This study compares a modified, less-invasive tumor removal approach with standard surgery for people with early stage (IB2) cervical cancer. It aims to see if this technique reduces the risk of cancer coming back while helping you heal faster.
Lanzhou, GansuAges 18–65 - NCT06840119RecruitingPhase 1/Phase 2
Experimental drug for advanced colorectal, esophageal, stomach, or ovarian cancer
This study tests an experimental drug called IMC-R117C for people with certain advanced cancers. It aims to see if the drug can shrink tumors or slow cancer growth.
Darlinghurst, SydneyAges 18 years+ - NCT06841055RecruitingPhase 2
Pumitamig plus chemo for Stage IV lung cancer after immunotherapy
This trial tests a new investigational drug called Pumitamig (BNT327) given with chemotherapy for people with advanced non-small cell lung cancer (Stage IV) that has continued to grow after one prior treatment with immunotherapy and platinum chemotherapy. The study aims to see if this combination is safe and can help shrink the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06876844RecruitingPhase 2
Surufatinib plus Envolizumab for advanced head and neck cancer
This study tests a new combination of two drugs (Surufatinib and Envolizumab) as a second treatment option for people with head and neck cancer that has returned or spread. It's for patients whose first treatment (usually chemo or immunotherapy) stopped working within 6 months.
ShanghaiAges 18–75
Hear when a new Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric cancer or gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 1,155 recruiting gastric cancer or gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal-junction Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.